Breztri Aerosphere Now Available in the US for Asthma
AstraZeneca's triple-combination asthma therapy Breztri Aerosphere was approved in April 2026 for adults and pediatric patients age 12 and older.
Tag: Breztri Aerosphere
Breztri Aerosphere Now Available in the US for Asthma
AstraZeneca’s triple-combination asthma therapy Breztri Aerosphere was approved in April 2026 for adults and pediatric patients age 12 and older.
Read More
FDA Approves Breztri for Asthma Patients 12+
The single-inhaler therapy Breztri Aerosphere is now indicated for maintenance treatment in adults and pediatric patients who remain symptomatic on dual therapies.
Read More
Positive Ph3 Trial Data Treating Uncontrolled Asthma with Breztri
AstraZeneca’s Breztri Aerosphere demonstrated statistically significant and clinically meaningful improvements in patients with uncontrolled asthma compared with other pharmacology.
Read More
Asthma Therapy Breztri Shows Lung Function Improvements in Phase III Trials
Two Phase III trials in patients with uncontrolled asthma found Breztri Aerosphere met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function.
Read More